Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026, 7:00 AM ET
Praxis reported a third quarter 2026 net loss of $94.2 million and $1.3 billion in cash, with runway into 2028.
Nasdaq: $PRAXNeurological medicinesTwo FDA review programsTrial and launch risk
PRAX Stock Hub: Praxis Precision Medicines News, Relutrigine and Ulixacaltamide
Two regulatory targets sit beside unresolved clinical and launch questions. Relutrigine has a December 27 target and ulixacaltamide a January 29 target; both FDA reviews were ongoing when Praxis reported third-quarter results on November 9. Cash, cash equivalents and marketable securities were about $1.3 billion at September 30, with runway guided into 2028. The November 9 regular-session close was $332.97 (+19.94%).
Full research report · PDF
Praxis Precision Medicines ($PRAX), research updated November 9, 2026
18 pages covering relutrigine and ulixacaltamide evidence, Essential 3 and EMERALD, regulatory review, the third-quarter 2026 accounts, launch costs, cash, dilution and trial-design risks. The report is dated; the hub follows later developments. For personal use only: redistribution prohibited.
Next announced company event
November 12, 2026 · 8:00 a.m. ET · Investor Day
Praxis hosts an in-person and virtual Investor Day in New York, with management presentations on commercial strategy and launch readiness for relutrigine and ulixacaltamide and on the development pipeline, joined by key opinion leaders. Q3 results were released before the market opened on November 9, and Praxis took part in a fireside chat at the Guggenheim Biotech Summit at 9:30 a.m. ET the same day. Company release
Relutrigine: December 27, 2026. Ulixacaltamide: January 29, 2027. Target dates are not approvals; EMERALD topline remains expected in Q4 2026 without an exact day.
PRAX stock at a glance
Close · November 9, 2026
$332.97
Regular session; +19.94% versus $277.62 on November 6.
Cash + investments · September 30
$1.286B
$361.9M cash and equivalents plus $924.2M marketable securities; company funding guidance into 2028.
Common shares · September 30
27.9M
Company-reported common shares, distinct from pre-funded warrants and awards.
Pre-funded warrants · September 30
1.24M
1,243,933 in three series, none exercised in 2026; potential common-share claims, not trading float.
ATM capacity · September 30
$250M
No shares sold in the first nine months of 2026; capacity, not cash received.
Relutrigine FDA target
December 27
2026 target action date, extended after a major amendment.
Ulixacaltamide FDA target
January 29
2027 target action date; separate indication and evidence package.
EMERALD clinical update
Q4 2026
Company guidance reaffirmed November 9; study in final stages, no exact release day.
Where Praxis Precision Medicines stands now
Praxis is preparing for potential commercial operations while two programs undergo regulatory review. Company-reported clean mid-cycle meetings and inspections do not guarantee the outcome. Relutrigine, ulixacaltamide and broader-DEE EMERALD evidence address different populations and uncertainties. September resources support preparation, while launch costs and future uptake will determine the operating result. Q3 2026 update · August regulatory update
On November 9, 2026 Praxis reported that both FDA reviews were ongoing, that the relutrigine commercial team was fully hired and that hiring of the ulixacaltamide field sales force was expected to be completed in Q4 2026. EMERALD, the relutrigine study in broad DEEs, is in the final stages of completion with topline expected in Q4 2026; the POWER2 study of vormatrigine has restarted with a revised design, and EMBRAVE3 topline for elsunersen is anticipated in 2027. Third-quarter general and administrative expense rose to $42.7 million from $12.6 million, mainly on personnel and professional costs, and the net loss was $94.2 million. Q3 2026 release
A clean review checkpoint does not settle approval, tolerability or access. Trial-design history, attrition, tolerability, broader-population replication, controlled launch spending and payer access remain material. A target date can change, and an approved label can be narrower than the commercial opportunity assumed. Awards, warrants and future issuance affect ownership.
The constructive case
Two reviewed applications, a funded development plan and identifiable clinical windows provide multiple execution tests if evidence, labels and access remain supportive.
The cautious case
The record includes failed endpoints and design questions, and first launches remain ahead. Regulatory or clinical setbacks can weaken assumptions while commercial preparation consumes cash.
Read also: Praxis $PRAX $RAPP $STOK $XENE: Beyond Seizure Counts →
Latest Praxis Precision Medicines news
Nov 9, 2026
Praxis Precision Medicines provides corporate update and reports third quarter 2026 financial results
Praxis reported a net loss of $94.2 million for the third quarter of 2026, compared to $73.9 million for the third quarter of 2025. Research and development expenses were $64.2 million and general and administrative expenses were $42.7 million. As of September 30, 2026, Praxis had $1.3 billion in cash, cash equivalents and marketable securities, expected to fund operations into 2028. The PDUFA target action dates are December 27, 2026 for relutrigine and January 29, 2027 for ulixacaltamide.
Nov 4, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
On November 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering 23,219 shares of common stock to fifty-nine new non-executive employees under the 2024 Inducement Plan. The awards were made as inducements material to the employees entering into employment with Praxis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to continued employment on each vesting date.
Oct 27, 2026
Q3 results and Investor Day scheduled
Results are scheduled before market open November 9, followed by a November 12 Investor Day at 8 a.m. ET addressing commercial readiness and the pipeline.
Oct 2, 2026
Employee inducement awards add potential issuance
The company disclosed inducement awards under its equity program. Vesting and eventual issuance are different from regulatory approval or product demand.
Sep 3, 2026
New hires receive share awards
Restricted stock units covering 11,535 shares were granted to 66 new employees effective September 1, with four-year vesting. Hiring supports preparation, not a regulatory conclusion.
Aug 6, 2026
June resources support the company funding plan
Cash and investments totaled $1.374 billion at June 30, with management estimating funding into 2028. Future spending and actual commercial outcomes can alter that estimate.
PRAX stock catalysts: results, Investor Day and two FDA targets
- November 9, 2026 — Q3 results released before the open: cash and investments of about $1.3 billion, runway into 2028, both FDA reviews ongoing; fireside chat at the Guggenheim Biotech Summit at 9:30 a.m. ET. Completed
- November 12, 2026 — Investor Day at 8 a.m. ET, in New York and online. Company schedule
- Q4 2026 — EMERALD clinical readout. Company window
- December 27, 2026 — Relutrigine target action date. FDA review target, not approval
- January 29, 2027 — Ulixacaltamide target action date. Separate FDA review target
- 2027 — EMBRAVE3 topline for elsunersen; planned start of the POWER3 monotherapy study of vormatrigine. Company expectation
Q3 2026 update · November events · Regulatory and clinical status
PRAX clinical evidence: Essential 3, relutrigine and EMERALD
The programs have separate designs and populations. Essential 3 interpretation includes trial history, attrition and tolerability; the relutrigine extension and broad-DEE study test different questions. Clean mid-cycle observations cannot replace the final benefit-risk assessment. On November 9, 2026 Praxis said EMERALD is in the final stages of completion, with topline expected in Q4 2026, and that it has reinitiated the long-term safety study tied to the Essential3 program so eligible patients can participate ahead of potential commercial availability. Q3 2026 update
PRAX cash resources and the first-launch test
At September 30, 2026 Praxis held $361.851 million in cash and cash equivalents and $924.175 million in marketable securities, about $1.3 billion, up $359.9 million from December 31, 2025 mainly because of the January 2026 follow-on offering; it expects these resources to fund operations into 2028. Third-quarter research and development expense was $64.2 million and general and administrative expense $42.7 million. Q3 2026 results Historical cash provides time, not a proven commercial model. Labels, treatment persistence, reimbursement and launch spending determine whether development progress produces durable revenue, while equity awards and financing can change the per-share outcome.
Merlintrader Health Score · $PRAX
3.8out of 5
Reassessed November 9, 2026 after the third-quarter results; scores unchanged from the October 2 assessment. Weighted calculation: 4.5×30% + 3.5×30% + 3.5×20% + 4.0×10% + 3.0×10% = 3.8. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- FDA target dates and clean checkpoints are not approvals.
- Trial designs, attrition, tolerability and replication remain program-specific.
- Funding guidance is conditional on spending and development assumptions.
- Launch costs, treatment persistence and potential issuance affect per-share economics.
PRAX Stock FAQ: Praxis Precision Medicines Questions Answered
What is the next PRAX stock catalyst?
Praxis reported Q3 2026 results on November 9, 2026. Its next announced event is the Investor Day on November 12 at 8 a.m. ET. The company still guides EMERALD topline to Q4 2026, while relutrigine (December 27, 2026) and ulixacaltamide (January 29, 2027) have separate FDA target dates. November 9 update with Investor Day details. August regulatory dates and EMERALD window.
When are Praxis’s relutrigine and ulixacaltamide FDA decisions?
Praxis’s August 6, 2026 update lists December 27, 2026 as relutrigine’s FDA target action date and January 29, 2027 for ulixacaltamide. Relutrigine’s application concerns SCN2A and SCN8A developmental and epileptic encephalopathies; ulixacaltamide concerns essential tremor. These are separate review programs and target dates, rather than approvals; on November 9 Praxis said both reviews were ongoing. Q3 2026 update. Applications, indications and target action dates.
How much cash does Praxis have, and how long is it funded?
Praxis held $361.851 million in cash and cash equivalents and $924.175 million in marketable securities at September 30, 2026, about $1.3 billion, and expects these resources to fund operations into 2028. The third-quarter net loss was $94.2 million. Q3 2026 results and funding outlook. Earlier, at June 30, it held $474.761 million cash and equivalents, $283.790 million current marketable securities and $615.290 million long-term marketable securities, with H1 operating cash use of $163.694 million. June balance sheet and H1 cash flows. Company funding and launch-preparation outlook.
How many PRAX shares are outstanding, and can Praxis issue more?
Praxis had 27,951,553 common shares outstanding on November 4, 2026, according to its third-quarter Form 10-Q. At September 30 it also reported 1,243,933 pre-funded warrants, 1,873,889 stock options and 664,323 unvested stock units that can add shares. No shares were sold under its $250 million ATM program in the first nine months of 2026; that capacity is not cash raised. On November 2 it granted inducement awards covering 23,219 shares. Q3 Form 10-Q. November 4 release.
When does Praxis Precision Medicines report Q3 2026 earnings?
Praxis released Q3 2026 financial results before U.S. markets opened on November 9, 2026: a net loss of $94.2 million, or $3.23 per share, and cash and investments of about $1.3 billion at September 30. It took part in a Guggenheim Biotech Summit fireside chat at 9:30 a.m. ET that day, and its Investor Day is scheduled for November 12 at 8 a.m. ET. As of November 9 the next results date had not been announced. Q3 2026 results. October 27 event schedule.
What does Praxis Precision Medicines do?
Praxis Precision Medicines develops medicines for central nervous system disorders using precision neuroscience. Its leading programs include relutrigine for developmental and epileptic encephalopathies and ulixacaltamide for essential tremor, alongside genetic-medicine programs such as elsunersen. It is building commercial capabilities ahead of potential regulatory approvals. Company pipeline and operating strategy.
Do Praxis’s clean FDA meetings mean its drugs will be approved?
Praxis’s August 6, 2026 update reported no major safety or efficacy concerns identified to date at mid-cycle meetings for either application, and no planned advisory committee meetings. It also reported BIMO inspections without Form FDA 483 observations. These describe review checkpoints; the agency still must complete its benefit-risk assessment and decide the labels. Mid-cycle meetings and inspection outcomes.
When are Praxis’s EMERALD relutrigine results expected?
Praxis’s August 6, 2026 guidance expects EMERALD topline results in Q4 2026, without an exact day; on November 9 the company said the study is in the final stages of completion and kept the Q4 2026 expectation. Approximately 200 patients spanning more than 50 genetically defined etiologies were enrolled. The broader-DEE study could support a supplemental application in 2027 if positive and if the initial relutrigine application is approved. EMERALD population, readout and conditional filing plan.
Primary sources
- November 9, 2026 · Q3 2026 results: about $1.3 billion, runway into 2028, FDA reviews ongoing, Investor Day on November 12
- October 27, 2026 · Q3 results and Investor Day scheduled
- October 2, 2026 · Employee inducement awards add potential issuance
- September 3, 2026 · New hires receive share awards
- August 6, 2026 · June resources support the company funding plan
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $PRAX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
